Comparison of patient characteristics between model development population (TH1), each of the validation populations and each of the validation periods (Mean±SD)
| Variable | TH1 | Time | TH2 | CH3 | CH4 | TH1B |
|---|---|---|---|---|---|---|
| N | 4883 | 6646/8561* | 6982/7765* | 5762/6787* | 10 069/13 068* | |
| Age | 60±18 | 2005–2008 | 67±18 | 74±16 | 74±16 | 60±18 |
| 2009–2012 | 66±18 | 74±16 | 74±17 | 59±18 | ||
| CCI | 3.0±2.9 | 2005–2008 | 3.0±2.3 | 2.5±2.1 | 2.1±1.8 | 2.9±2.4 |
| 2009–2012 | 3.0±2.4 | 2.8±2.1 | 2.9±2.1 | 3.1±2.5 | ||
| ADLS | 13.7±12.4 | 2005–2008 | 12.0±11.3 | 16.1±12.4 | 15.8±12.8 | 13.6±12.5 |
| 2009–2012 | 12.4±11.6 | 16.9±13.9 | 17.9±12.5 | 9.4±12.4 | ||
| GCS† | 81% | 2005–2008 | 79% | 75% | 70% | 81% |
| 2009–2012 | 78% | 72% | 64% | 83% | ||
| HR | 86.1±20.7 | 2005–2008 | 84.8±19.8 | 84.1±20.01 | 83.4±20.5 | 85.6±19.8 |
| 2009–2012 | 86.1±18.2 | 83.9±19.0 | 83.6±19.1 | 86.6±19.1 | ||
| RR | 20.4±4.3 | 2005–2008 | 20.3±4.4 | 20.6±4.3 | 19.6±3.8 | 19.9±4.2 |
| 2009–2012 | 19.3±4.1 | 19.8±3.8 | 19.3±4.3 | 19.3±4.2 | ||
| WCC | 10.2±8.4 | 2005–2008 | 10.7±10.4 | 10.7±6.6 | 10.0±7.5 | 10.6±9.7 |
| 2009–2012 | 11.2±10.3 | 11.2±8.7 | 10.7±8.0 | 11.4±12.2 | ||
| SBP | 129±31 | 2005–2008 | 130±27 | 131±27 | 135±29 | 133±28 |
| 2009–2012 | 129±25 | 131±24 | 132±25 | 132±26 | ||
| Male | 52% | 2005–2008 | 48% | 47% | 43% | 53% |
| 2009–2012 | 49% | 48% | 45% | 52% |
Age in years.
*Sample sizes in the 2005–2008 and 2009–2012 validation periods.
†Percentage of patients with maximum GCS (15).
ADLS, Activities of Daily Living Score; CCI, Charlson Comorbidity Index; GCS, Glasgow Coma Score; HR, heart rate as beats per minute; RR, respiratory rate as breaths per minute; SBP, systolic blood pressure as mm of Hg; WCC, white cell count as cells per mL3 divided by 103.